Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

A. C. Bester; M. Schwartz; M. Schmidt; A. Garrigue; S. Hacein-Bey-Abina; M. Cavazzana-Calvo; N. Ben-Porat; C. Von Kalle; A. Fischer; B. Kerem

doi:10.1038/sj.gt.3302752

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

A. C. Bester, M. Schwartz, M. Schmidt, A. Garrigue, S. Hacein-Bey-Abina, M. Cavazzana-Calvo, N. Ben-Porat, C. Von Kalle, A. Fischer, B. Kerem^*

^*Corresponding author for this work

Department of Genetics

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.

Original language	English
Pages (from-to)	1057-1059
Number of pages	3
Journal	Gene Therapy
Volume	13
Issue number	13
DOIs	https://doi.org/10.1038/sj.gt.3302752
State	Published - Jul 2006

Keywords

Fragile sites
LMO2
Leukemia
Viral integration

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.gt.3302752

Cite this

@article{4026deb0877544ddb9a8108ad6cf3837,

title = "Fragile sites are preferential targets for integrations of MLV vectors in gene therapy",

abstract = "Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.",

keywords = "Fragile sites, LMO2, Leukemia, Viral integration",

author = "Bester, {A. C.} and M. Schwartz and M. Schmidt and A. Garrigue and S. Hacein-Bey-Abina and M. Cavazzana-Calvo and N. Ben-Porat and {Von Kalle}, C. and A. Fischer and B. Kerem",

year = "2006",

month = jul,

doi = "10.1038/sj.gt.3302752",

language = "אנגלית",

volume = "13",

pages = "1057--1059",

journal = "Gene Therapy",

issn = "0969-7128",

publisher = "Springer Nature",

number = "13",

}

TY - JOUR

T1 - Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

AU - Bester, A. C.

AU - Schwartz, M.

AU - Schmidt, M.

AU - Garrigue, A.

AU - Hacein-Bey-Abina, S.

AU - Cavazzana-Calvo, M.

AU - Ben-Porat, N.

AU - Von Kalle, C.

AU - Fischer, A.

AU - Kerem, B.

PY - 2006/7

Y1 - 2006/7

N2 - Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.

AB - Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.

KW - Fragile sites

KW - LMO2

KW - Leukemia

KW - Viral integration

UR - http://www.scopus.com/inward/record.url?scp=33745225238&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302752

DO - 10.1038/sj.gt.3302752

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16511518

AN - SCOPUS:33745225238

SN - 0969-7128

VL - 13

SP - 1057

EP - 1059

JO - Gene Therapy

JF - Gene Therapy

IS - 13

ER -

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this